<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472028</url>
  </required_header>
  <id_info>
    <org_study_id>P100153</org_study_id>
    <secondary_id>2014 A00265-42</secondary_id>
    <nct_id>NCT02472028</nct_id>
  </id_info>
  <brief_title>Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals</brief_title>
  <acronym>LEOPOLD</acronym>
  <official_title>LEukoaraiosis and blOod Pressure Reduction in OLD People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the hypothesis of slowing the progression of White Matter&#xD;
      Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a&#xD;
      moderate to high grade of WML on brain MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCIENTIFIC BACKGROUND: White Matter Lesions (WML) are cerebrovascular abnormalities&#xD;
      discovered on MRI that are associated with an increased risk of dementia. High blood pressure&#xD;
      (BP) is a major risk factor for WML. WML are therefore key lesions in the causal chain&#xD;
      linking vascular factors and dementia, particularly Alzheimer's disease.&#xD;
&#xD;
      However, it has not been shown that lowering BP could limit the progression of the WML in&#xD;
      people with cognitive impairment.&#xD;
&#xD;
      OBJECTIVES: To test the hypothesis of slowing progression of WML by lowering BP in patients&#xD;
      with memory complaints with a moderate to high grade of WML on brain MRI.&#xD;
&#xD;
      STUDY DESIGN: PROBE (Prospective randomized open blinded end-point) trial. Blind reading of&#xD;
      both MRI for every patient in each group. After stratified randomization on age, sex and&#xD;
      center, patients will be assigned to two strategies:&#xD;
&#xD;
        -  Reinforced Group (RG): enhanced strategy aiming at a systolic BP &lt;135 mmHg;&#xD;
&#xD;
        -  Usual Group (UG): usual strategy based on the usual routine care.&#xD;
&#xD;
      SAMPLE SIZE: patients will be enrolled (410 in each arm) in 12 Memory Resources and Research&#xD;
      Center (CMRR) with access to 1.5 T or more MRI.&#xD;
&#xD;
      CONDUCT OF THE STUDY:&#xD;
&#xD;
      Duration of the inclusion period: 71 months and 2 weeks. Patient participation duration: 36&#xD;
      months +/- 2 weeks Total study duration: 9 years. Clinical and para-clinical evaluation: MRI&#xD;
      as part of research at the beginning of the study and before the end of the study at 36&#xD;
      months (primary endpoint); Clinical evaluation of neuropsychological tests at the beginning&#xD;
      of the study and yearly ; walking speed measurement single leg stance balance test ; repeated&#xD;
      BP measurements; monitoring of neurological signs and symptoms; blood test at the beginning&#xD;
      of the study (electrolytes, lipid profiles, fasting blood glucose, if not existing); MRI if&#xD;
      not existing for validation of the inclusion criterion and performed in the ordinary course.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main criterion is based on the quantitative assessment of White Matter Lesions (WML) volumes at the beginning and at the end of the study for each patient and each arm of the trial. The WML volume from the final MRI is compared to that of the initial</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imaging criteria : changes in the number of large or confluent WML</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging criteria : changes in the volume of WML depending on their location (periventricular and deep white matter)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging criteria : changes in the number of silent infarctus</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging criteria : changes in the number of microbleeds</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging criteria : evolution of brain volumes (gray matter, white matter, CSF, and regional volumes including hippocampus)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical criteria: clinical criteria (changes in neuropsychological tests</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical criteria: changes inwalking speed</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical criteria: number of incident cases of dementia</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incident cases of vascular events validated by an expert committee</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical criteria: total mortality by cause</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>blood pressure lowering algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enhanced strategy aiming to reduce systolic blood pressure to &lt;135 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>usual strategy based on the usual care of routine care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood pressure lowering algorithm</intervention_name>
    <description>The treatments used in the &quot;enhanced strategy&quot; arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study.</description>
    <arm_group_label>blood pressure lowering algorithm</arm_group_label>
    <other_name>enhanced strategy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual strategy</intervention_name>
    <description>The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.</description>
    <arm_group_label>usual strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60 to 88 years old patients;&#xD;
&#xD;
          -  Patient with cognitive complaint with MMSE ≥ 20performed within 6 months prior to&#xD;
             enrollment (with or without dementia)&#xD;
&#xD;
          -  Patient with a socio-educational level ≥ 3&#xD;
&#xD;
          -  Presence of hyperintensities of moderate to high grade on the last MRI or old scan&#xD;
             (grades C and D on the modified Scheltens scale, grades 2/3 Fazekas).&#xD;
&#xD;
          -  Hypertension defined by a Systolic Blood Pressure (SBP) and / or a Diastolic Blood&#xD;
             Pressure (DBP) ≥ 140/90 mmHg, treated or not&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
          -  Informed consent given, signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of severe orthostatic hypotension defined as a decrease of 30 mmHg in SBP&#xD;
             standing within 3 minutes&#xD;
&#xD;
          -  Contraindication to MRI (presence of ferromagnetic foreign body (especially some&#xD;
             intracranial clips, some heart valves, intraocular foreign bodies, metal prosthesis),&#xD;
             subject carrying pacemaker, claustrophobic participants)&#xD;
&#xD;
          -  Severe diseases associated with a life expectancy of less than 3 months;&#xD;
&#xD;
          -  Major physical impairments that can interfere with the feasibility of the tests&#xD;
             (sight, hearing ...)&#xD;
&#xD;
          -  Presence of another dementia different than Alzheimer's disease vascular dementia or&#xD;
             mixed dementia,&#xD;
&#xD;
          -  Persons under guardianship;&#xD;
&#xD;
          -  Secondary hypertension: renovascular hypertension, primary aldosteronism,&#xD;
             pheochromocytoma ...;&#xD;
&#xD;
          -  Patient already receiving 4 or more antihypertensive drugs at maximum dosage&#xD;
&#xD;
          -  Patient participating in another clinical research study on drug requiring exclusion&#xD;
             period&#xD;
&#xD;
          -  severe renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe TZOURIO, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inserm U897 - Bordeaux University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier HANON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier HANON, MD, PhD</last_name>
    <phone>33 1 44 08 35 02</phone>
    <email>olivier.hanon@brc.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe TZOURIO, MD, PhD</last_name>
    <email>christophe.tzourio@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memory for Research and Resources Center / Neuroscience pole</name>
      <address>
        <city>Bordeaux</city>
        <state>Pellegrin Hospital Group</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Tzourio, MD, PhD</last_name>
      <phone>+33 (0)5 57 57 16 59</phone>
      <email>christophe.tzourio@u-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie DEBETTE, MD, PhD</last_name>
      <phone>Tel: +33 (0) 5 57 57 16 59</phone>
      <email>stephanie.debette@isped.u-bordeaux2.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memory Resources Centre and South of Ile de France Search - Broca Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HANON, MD, PhD</last_name>
      <phone>33 1 44 08 35 02</phone>
      <email>olivier.hanon@brc.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie DEBETTE, MD, PhD</last_name>
      <phone>+33 (0) 5 57 57 16 59</phone>
      <email>stephanie.debette@isped.u-bordeaux2.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier HANON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Stroke</keyword>
  <keyword>Antihypertensive Agents</keyword>
  <keyword>Arterial Pressure</keyword>
  <keyword>Memory Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

